Olema Pharmaceuticals, Inc.

Healthcare · Biotechnology · United States

Last price 7.33 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 641.36M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. The company’s lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in seco...